SiBone (NASDAQ:SIBN) CEO Laura Francis Sells 38,006 Shares of Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 38,006 shares of the business’s stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $20.05, for a total value of $762,020.30. Following the completion of the sale, the chief executive officer owned 379,256 shares of the company’s stock, valued at $7,604,082.80. The trade was a 9.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Laura Francis also recently made the following trade(s):

• On Monday, August 24th, Laura Francis sold 25,972 shares of SiBone stock. The shares were sold at an average price of $20.12, for a total value of $522,556.64.
• On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total value of $78,538.46.
• On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total transaction of $1,009,662.64.

SiBone Trading Down 1.1%

Shares of NASDAQ SIBN traded down $0.21 during mid-day trading on Wednesday, hitting $19.47. The stock had a trading volume of 407,809 shares, compared to its average volume of 610,528. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15. SiBone has a 1 year low of $11.48 and a 1 year high of $21.89. The business has a 50 day moving average price of $18.89 and a two-hundred day moving average price of $16.43. The firm has a market cap of $863.49 million, a P/E ratio of -57.26 and a beta of 0.66.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.06. The company had revenue of $56.01 million during the quarter, compared to analyst estimates of $55.34 million. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. On average, equities analysts anticipate that SiBone will post -0.40 EPS for the current fiscal year.

Hedge Funds Weigh In On SiBone

A number of hedge funds have recently added to or reduced their stakes in SIBN. Versant Capital Management Inc increased its position in shares of SiBone by 102.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after purchasing an additional 887 shares during the last quarter. State of Wyoming grew its position in SiBone by 70.8% during the first quarter. State of Wyoming now owns 10,832 shares of the company’s stock valued at $137,000 after buying an additional 4,490 shares during the period. Inceptionr LLC bought a new stake in SiBone during the first quarter valued at approximately $156,000. ADAR1 Capital Management LLC purchased a new stake in SiBone during the first quarter valued at approximately $159,000. Finally, Elevation Point Wealth Partners LLC purchased a new stake in SiBone during the first quarter valued at approximately $204,000. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently issued reports on SIBN. Truist Financial boosted their target price on SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday. UBS Group lifted their price target on shares of SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. TD Cowen boosted their price objective on shares of SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Finally, Weiss Ratings upgraded shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $24.50.

SiBone Company Profile

SI-BONE, Inc is a medical device company focused on developing and commercializing products for the surgical treatment of disorders affecting the sacroiliac joint, which connects the spine to the pelvis. The company’s technology is intended to support minimally invasive procedures for patients with sacroiliac joint dysfunction and related conditions.

Its product portfolio includes the iFuse Implant System, a family of triangular titanium implants designed to stabilize and fuse the sacroiliac joint.